Related Experiment Video
Updated: Nov 28, 2025
09:29
An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
1.1K
Galectin-9: A Suppressor of Atherosclerosis?
Jian Yu1, Ruirui Zhu1, Kuwu Yu1
1Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in Immunology
|November 30, 2020
Summary
Galectin-9 (Gal-9) regulates T-cell immunity and may offer a novel therapy for atherosclerosis, a chronic inflammatory vascular disease. Blocking its interaction with T-cell immunoglobulin mucin 3 (TIM-3) worsened plaque formation.
Area of Science:
- Immunology
- Cardiovascular Research
- Inflammatory Diseases
Background:
- Atherosclerosis is a chronic inflammatory disease of the vascular wall, involving innate and adaptive immune cells.
- Galectin-9 (Gal-9) is a key regulator of T-cell immunity, influencing autoimmune and inflammatory conditions.
- Gal-9 signaling via T-cell immunoglobulin mucin 3 (TIM-3) modulates immune responses, including T-cell populations, macrophages, and myeloid-derived suppressor cells.
Purpose of the Study:
- To investigate the potential therapeutic role of Galectin-9 in atherosclerosis.
- To explore the impact of Gal-9/TIM-3 pathway modulation on the development of atherosclerotic disease.
Main Methods:
- Review of existing literature on Gal-9, TIM-3, and their roles in immunity and atherosclerosis.
- Analysis of studies investigating the effects of anti-TIM-3 antibody administration on atherosclerotic plaque formation.
Main Results:
- Gal-9 signaling via TIM-3 plays a critical role in regulating T-cell immunity and immune cell polarization.
- Blocking the Gal-9/TIM-3 interaction with anti-TIM-3 antibodies exacerbated atherosclerotic plaque formation, suggesting a protective role for this interaction.
Conclusions:
- Galectin-9 demonstrates potential as a novel therapeutic agent for atherosclerotic disease.
- Further research is warranted to elucidate the precise mechanisms of Gal-9 in atherosclerosis and to validate its therapeutic efficacy.
Related Concept Videos
01:26Atherosclerosis III: Management
197
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
197
01:30Atherosclerosis I: Introduction
503
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
503
01:09GPCRs Regulate Adenylyl Cylase Activity
6.5K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.5K
01:16TGF - β Signaling Pathway
9.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
9.7K
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
261
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
261
01:12GPCR Desensitization
7.4K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.4K